Solonex Co 300 mg/300 mg FC tablet
PDF Leaflet Revision Date: 29 August 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of active tuberculosis in high-risk adults with latent TB infection.
Dosage (summary)
Once-weekly for 12 weeks; max 900 mg isoniazid and rifapentine based on weight.
Special Populations
- Elderly
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; contraindicated in breastfeeding.
Key Drug Interactions
- Protease inhibitors
- NNRTIs
- Hormonal contraceptives
Contraindications
- Hypersensitivity to isoniazid or rifapentine
- Severe renal failure
- Acute liver disease
- Alcoholism
Common side effects
- Nausea
- Headache
- Hepatitis
- Skin reactions
Counselling Points
- Take with food
- Do not miss doses
- Monitor for hypersensitivity reactions
Serious warnings
- Hepatotoxicity
- Severe cutaneous adverse reactions
- Clostridium difficile-associated diarrhoea
Important Disclaimer
The Solonex Co 300 mg/300 mg FC tablet professional information leaflet below is the property of Macleods Pharmaceuticals Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
